BioSpace News Archive

Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.

Curis, Inc. announced that on October 2, 2023, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 11,340 shares of Curis common stock to two new employees, with a grant date of October 2, 2023.

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.

GE HealthCare announced its Venue Family point-of-care ultrasound systems will now feature Caption Guidance, artificial intelligence -driven technology that provides real-time guidance to users for capturing diagnostic-quality cardiac images.

Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, commends leading researchers in women’s health, who presented data showing that urinary incontinence (UI) symptom relief is durable for two-years following eight-weeks of treatment with the Leva® Pelvic Health System.

Advanced Infusion Care (AIC), a division of AIS Healthcare, today announced its participation in the Immunoglobulin National Society (IgNS) 12th National Conference, which takes place on October 5th – 8th in Denver, Colorado.

Addex Therapeutics announced that it plans to change the ratio of its American Depositary Shares to its ordinary shares from the current ADS Ratio of one ADS to six ordinary shares to a new ADS Ratio of one ADS to one hundred and twenty ordinary shares.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to four new employees.

Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication, announced that Richie Cunningham has been appointed as Anebulo’s Chief Executive Officer, replacing Simon Allen.